Literature DB >> 35796614

Testosterone undecanoate administration prevents declines in fat-free mass but not physical performance during simulated multi-stressor military operations.

Alyssa N Varanoske1,2, Melissa N Harris3, Callie Hebert3, Emily E Howard1,2, Neil M Johannsen3, Steven B Heymsfield3, Frank L Greenway3, Lee M Margolis1, Harris R Lieberman1, Robbie A Beyl3, David D Church4, Arny A Ferrando4, Stefan M Pasiakos5, Jennifer C Rood3.   

Abstract

Male military personnel conducting strenuous operations experience reduced testosterone concentrations, muscle mass, and physical performance. Pharmacological restoration of normal testosterone concentrations may attenuate performance decrements by mitigating muscle mass loss. Previously, administering testosterone enanthate (200 mg/wk) during 28 days of energy deficit prompted supraphysiological testosterone concentrations and lean mass gain without preventing isokinetic/isometric deterioration. Whether administering a practical dose of testosterone protects muscle and performance during strenuous operations is undetermined. The objective of this study was to test the effects of a single dose of testosterone undecanoate on body composition and military-relevant physical performance during a simulated operation. After a 7-day baseline phase (P1), 32 males (means ± SD; 77.1 ± 12.3 kg, 26.5 ± 4.4 yr) received a single dose of either testosterone undecanoate (750 mg; TEST) or placebo (PLA) before a 20-day simulated military operation (P2), followed by a 23-day recovery (P3). Assessments included body composition and physical performance at the end of each phase and circulating endocrine biomarkers throughout the study. Total and free testosterone concentrations in TEST were greater than PLA throughout most of P2 (P < 0.05), but returned to P1 values during P3. Fat-free mass (FFM) was maintained from P1 to P2 in TEST (means ± SE; 0.41 ± 0.65 kg, P = 0.53), but decreased in PLA (-1.85 ± 0.69 kg, P = 0.01) and recovered in P3. Regardless of treatment, total body mass and fat mass decreased from P1 to P2 (P < 0.05), but did not fully recover by P3. Physical performance decreased during P2 (P < 0.05) and recovered by P3, regardless of treatment. In conclusion, administering testosterone undecanoate before a simulated military operation protected FFM but did not prevent decrements in physical performance.NEW & NOTEWORTHY This study demonstrated that a single intramuscular dose of testosterone undecanoate (750 mg) administered to physically active males before a 20-day simulated, multi-stressor military operation increased circulating total and free testosterone concentrations within normal physiological ranges and spared FFM. However, testosterone administration did not attenuate decrements in physical performance across multiple measures of power, strength, anaerobic or aerobic capacity.

Entities:  

Keywords:  energy deficit; hypogonadism; lean body mass; skeletal muscle; strength

Mesh:

Substances:

Year:  2022        PMID: 35796614      PMCID: PMC9359646          DOI: 10.1152/japplphysiol.00190.2022

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  55 in total

1.  Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults.

Authors:  Jaehee Kim; Stanley Heshka; Dympna Gallagher; Donald P Kotler; Laurel Mayer; Jeanine Albu; Wei Shen; Pamela U Freda; Steven B Heymsfield
Journal:  J Appl Physiol (1985)       Date:  2004-04-16

2.  Recovery of endocrine and inflammatory mediators following an extended energy deficit.

Authors:  Paul C Henning; Dennis E Scofield; Barry A Spiering; Jeffery S Staab; Ronald W Matheny; Martha A Smith; Shalender Bhasin; Bradley C Nindl
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

3.  Calculated free testosterone in men: comparison of four equations and with free androgen index.

Authors:  Clement K M Ho; Mary Stoddart; Melanie Walton; Richard A Anderson; Geoffrey J Beckett
Journal:  Ann Clin Biochem       Date:  2006-09       Impact factor: 2.057

Review 4.  Clinical practice update on testosterone therapy for male hypogonadism: Contrasting perspectives to optimize care.

Authors:  Bu B Yeap; Frederick C W Wu
Journal:  Clin Endocrinol (Oxf)       Date:  2018-12-03       Impact factor: 3.478

5.  A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.

Authors:  G Y Zhang; Y Q Gu; X H Wang; Y G Cui; W J Bremner
Journal:  J Androl       Date:  1998 Nov-Dec

Review 6.  Onset of effects of testosterone treatment and time span until maximum effects are achieved.

Authors:  Farid Saad; Antonio Aversa; Andrea M Isidori; Livia Zafalon; Michael Zitzmann; Louis Gooren
Journal:  Eur J Endocrinol       Date:  2011-07-13       Impact factor: 6.664

Review 7.  Effect of Special Operations Training on Testosterone, Lean Body Mass, and Strength and the Potential for Therapeutic Testosterone Replacement: A Review of the Literature.

Authors:  Jon K Linderman; Reginald O'Hara; Jason Ordway
Journal:  J Spec Oper Med       Date:  2020

8.  Effects of testosterone undecanoate on performance during multi-stressor military operations: A trial protocol for the Optimizing Performance for Soldiers II study.

Authors:  Alyssa N Varanoske; Melissa N Harris; Callie Hebert; Emily E Howard; Neil M Johannsen; Steven B Heymsfield; Frank L Greenway; Lee M Margolis; Harris R Lieberman; David D Church; Arny A Ferrando; Jennifer C Rood; Stefan M Pasiakos
Journal:  Contemp Clin Trials Commun       Date:  2021-07-03

9.  The catecholamine neurotransmitter precursor tyrosine increases anger during exposure to severe psychological stress.

Authors:  Harris R Lieberman; Lauren A Thompson; Christina M Caruso; Philip J Niro; Caroline R Mahoney; James P McClung; Gregory R Caron
Journal:  Psychopharmacology (Berl)       Date:  2014-09-16       Impact factor: 4.530

10.  Muscular responses to testosterone replacement vary by administration route: a systematic review and meta-analysis.

Authors:  Jared W Skinner; Dana M Otzel; Andrew Bowser; Daniel Nargi; Sanjay Agarwal; Mark D Peterson; Baiming Zou; Stephen E Borst; Joshua F Yarrow
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-03-15       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.